Abstract

The aim of this project is to promote the integration of clinical cancer therapeutic research in the Mid-South area by joining a university-based cancer center with the major teaching and regional hospitals in a cooperative group effort. The University of Tennessee will continue to use its membership in Cancer and Leukemia Group B to support participation in therapeutic research and other clinical trials both in the University hospital complex and its affiliated institutions. The goals are the initiation and participation in phase I, II, and III cooperative clinical trials involving chemotherapy, surgery, and radiation therapy. A major emphasis is the development of new therapeutic strategies in collaborative investigations with interested members of CALGB. Data collection, monitoring, reporting, and publication of information is a primary emphasis. University of Tennessee members will continue to be actively involved in scientific and administrative committees of CALGB.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10CA047555-15
Application #
6512618
Study Section
Subcommittee G - Education (NCI)
Program Officer
Mooney, Margaret M
Project Start
1988-04-01
Project End
2003-03-31
Budget Start
2002-04-12
Budget End
2003-03-31
Support Year
15
Fiscal Year
2002
Total Cost
$25,069
Indirect Cost

  Institution

Name
University of Tennessee Health Science Center
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
941884009
City
Memphis
State
TN
Country
United States
Zip Code
38163

  Publications

Jeon, Justin; Sato, Kaori; Niedzwiecki, Donna et al. (2013) Impact of physical activity after cancer diagnosis on survival in patients with recurrent colon cancer: Findings from CALGB 89803/Alliance. Clin Colorectal Cancer 12:233-8
Ogino, Shuji; Liao, Xiaoyun; Imamura, Yu et al. (2013) Predictive and prognostic analysis of PIK3CA mutation in stage III colon cancer intergroup trial. J Natl Cancer Inst 105:1789-98
Lichtman, S M; Hurria, A; Cirrincione, C T et al. (2012) Paclitaxel efficacy and toxicity in older women with metastatic breast cancer: combined analysis of CALGB 9342 and 9840. Ann Oncol 23:632-8
Lara, Jonathan F; Thor, Ann D; Dressler, Lynn G et al. (2011) p53 Expression in node-positive breast cancer patients: results from the Cancer and Leukemia Group B 9344 Trial (159905). Clin Cancer Res 17:5170-8
Ng, Kimmie; Ogino, Shuji; Meyerhardt, Jeffrey A et al. (2011) Relationship between statin use and colon cancer recurrence and survival: results from CALGB 89803. J Natl Cancer Inst 103:1540-51
Baer, M R; George, S L; Sanford, B L et al. (2011) Escalation of daunorubicin and addition of etoposide in the ADE regimen in acute myeloid leukemia patients aged 60 years and older: Cancer and Leukemia Group B Study 9720. Leukemia 25:800-7
Graziano, Stephen L; Gu, Lin; Wang, Xiaofei et al. (2010) Prognostic significance of mucin and p53 expression in stage IB non-small cell lung cancer: a laboratory companion study to CALGB 9633. J Thorac Oncol 5:810-7
Smith, S M; Johnson, J; Cheson, B D et al. (2009) Recombinant interferon-alpha2b added to oral cyclophosphamide either as induction or maintenance in treatment-naive follicular lymphoma: final analysis of CALGB 8691. Leuk Lymphoma 50:1606-17
Grinblatt, David L; Yu, Daohai; Hars, Vera et al. (2009) Treatment of myelodysplastic syndrome with 2 schedules and doses of oral topotecan: a randomized phase 2 trial by the Cancer and Leukemia Group B (CALGB 19803). Cancer 115:84-93
Stone, Richard M; Donohue, Kathleen A; Stock, Wendy et al. (2009) A phase II study of continuous infusion homoharringtonine and cytarabine in newly diagnosed patients with chronic myeloid leukemia: CALGB study 19804. Cancer Chemother Pharmacol 63:859-64

Showing the most recent 10 out of 61 publications